Background/Aims: The overexpression of ATP-Binding Cassette (ABC) transporters has known to be one of the major obstacles impeding the success of chemotherapy in drug resistant cancers. In this study, we evaluated voruciclib, a CDK 4/6 inhibitor, for its chemo-sensitizing activity in ABCB1-and ABCG2-overexpressing cells. Methods: Cytotoxicity and reversal effect of voruciclib was determined by MTT assay. The intracellular accumulation and efflux of ABCB1 and ABCG2 substrates were measured by scintillation counter. The effects on expression and intracellular localization of ABCB1 and ABCG2 proteins were determined by Western blotting and immunofluorescence, respectively. Vanadate-sensitive ATPase assay was done to determine the effect of voruciclib on the ATPase activity of ABCB1 and ABCG2. Flow cytometric analysis was done to determine the effect of voruciclib on apoptosis of ABCB1 and ABCG2-overexpressing cells and docking analysis was done to determine the interaction of voruciclib with ABCB1 and ACBG2 protein. Results: Voruciclib significantly potentiated the effect of paclitaxel and doxorubicin in ABCB1-overexpressing cells, as well as mitoxantrone and SN-38 in ABCG2-overexpressing cells. Voruciclib moderately sensitized ABCC10-overexpressing cells to paclitaxel, whereas it did not alter the cytotoxicity of substrates of ABCC1. Furthermore, voruciclib increased the intracellular accumulation and decreased the efflux of substrate anti-cancer drugs from ABCB1-or ABCG2-overexpressing cells. However, voruciclib did not alter the expression or the sub-cellular localization of ABCB1 or ABCG2. Voruciclib stimulated the ATPase activity of both ABCB1 and ABCG2 in a concentration-dependent manner. Lastly, voruciclib exhibited a drug-induced apoptotic effect in ABCB1-or ABCG2-overexpressing cells. Conclusion: Voruciclib is currently a phase I clinical trial drug. Our findings strongly support its potential use in combination with conventional anti-cancer drugs for cancer chemotherapy.
Introduction
Multidrug resistance (MDR), defined as the resistance to chemotherapeutic drugs that are not similar in their chemical structure and mechanism of action, hinders the success of chemotherapy [1, 2] . Over the years, a number of intrinsic and extrinsic cellular mechanisms have been identified and reported to cause MDR in cancer cells, some of which include, alteration in cyclin-dependent kinases (CDKs), regulation of apoptosis, autophagy, and increased DNA repair mechanisms [3] [4] [5] [6] . However, the ABC transporters-mediated efflux of chemotherapeutic drugs is the most prominent factor leading to the development of MDR [7, 8] .
Located on the plasma membrane of cells, ABC transporter is a super family consisting of 49 members classified into seven subfamilies (A-G), out of which ABCB1, ABCG2 and ABCCs are well documented to induce MDR in cancer cells [5, 9] . ABCB1, also known as P-glycoprotein (P-gp), is ubiquitously expressed in kidney, intestine, brain, and placenta [2] . ABCB1 effluxes a number of chemotherapeutic drugs like paclitaxel, doxorubicin, and vincristine [1, 2, 10] . ABCG2, also known as breast cancer resistance protein (BCRP), is expressed on the apical surface of small intestines, liver canalicular membrane, colon epithelium, and in placental syncytiotrophoblasts [9, 11] . Some common substrates of ABCG2 include mitoxantrone, SN-38, and topotecan [12, 13] . Since, the efflux function of ABCB1 and ABCG2 prevents the normal cells from building up toxins; their actions are considered to be protective and homeostatic. Contrastingly, in cancer cells, the efflux function causes a decrease in intracellular concentration of the chemotherapeutic drugs and thus, the actions of ABCB1 and ABCG2 are deleterious.
Over the past three decades, a number of efflux function modulators have been developed and investigated for their inhibitory action against ABCB1 and ABCG2-mediated MDR [7, [14] [15] [16] . Voruciclib, a CDK4/6 inhibitor, has shown promising anti-cancer effects in combination with the BRAF inhibitor, vemurafenib in advanced BRAF-mutant melanoma [17] . More recent studies have shown that voruciclib enhances the sensitivity of the proteasome inhibitor, bortezomib, in triple negative breast cancer xenografts [18] . However, there is no published data indicating the sensitizing effects of voruciclib in cells overexpressing ABC transporters. Here, for the first time, we report that voruciclib blocks the efflux function of ABCB1 and ABCG2 and sensitizes cancer cells to chemotherapeutic drugs.
Materials and Methods
Reagents Voruciclib (Fig. 1A) was obtained from ChemieTek (Indianapolis, IN). Dulbecco's modified Eagle's Medium (DMEM), fetal bovine serum (FBS), penicillin/streptomycin and trypsin 0.25% were purchased from Hyclone (Pittsburgh, PA). Monoclonal antibody against ABCB1, ABCG2, and beta-actin were purchased from Thermo Fisher Scientific Inc. (Rockford, IL). Alexa Fluor 488 conjugated goat anti-mouse IgG secondary antibody and SN-38 were also purchased from Thermo Fisher Scientific Inc. (Rockford, IL). Paclitaxel, doxorubicin, vincristine, cisplatin, mitoxantrone, and verapamil were purchased from SigmaAldrich (St. Louis, MO). H]-mitoxantrone (2.5 Ci/mmol) were purchased from Moravek Biochemicals, Inc (Brea, CA). Propidium iodide (PI) and Annexin-V were purchased from BD biosciences (San Jose, CA). The chemicals for the ATPase assay were similar to those used in our previous study [19] . Fumitremorgin C (FTC) was a gift from Dr. Susan Bates (Columbia University, NY).
Cell lines and cell culture
The human colorectal adenocarcinoma cell line SW620, its doxorubicin-selected SW620/AD300 cell line, the porcine kidney epithelial cell line LLC-PK1 and LLC-PK1/MDR1 (transfected with human ABCB1 cDNA [20] ) were used for ABCB1 reversal study. The non-small cell lung cancer cell line NCI-H460, its mitoxantrone-selected NCI-H460/MX20, and HEK293 cells transfected with either empty pcDNA3.1 vector (HEK293/pcDNA3.1) or vector containing wild type ABCG2 (HEK/ABCG2-R482) or mutants of ABCG2 (HEK/ABCG2-R482G and HEK/ABCG2-R482T) were used for ABCG2 reversal study. HEK293/ABCC1 and HEK293/ ABCC10 cells were generated by transfecting the HEK293 cells with ABCC1 or ABCC10 expression vector, respectively [21] . The transfected cells were cultured in a medium containing 2 mg/mL of G418 and all other cell lines were cultured at 37°C, 5% CO 2 with DMEM containing 10% FBS and 1% penicillin/streptomycin.
MTT assay
The modified MTT colorimetric assay was used to detect the sensitivity of cells to anticancer drugs in vitro as previously described [19, 22] . The cells were trypsinized and resuspended in a final concentration of 4 × 10 3 cells/well. The cells were seeded into 96 well plates and incubated for 24 h. Subsequently, 20 μl of voruciclib at the indicated concentrations (0-100 μM) was added to determine its cytotoxicity. In order to investigate the reversal effects of voruciclib, different concentrations of chemotherapeutic drugs (20 μl/ well) were added after pre-incubation with voruciclib, verapamil, or FTC for 2 h. After 72 h of incubation, MTT reagent (4 mg/ml and 20 μl/ well) was added and the plates were further incubated for 4 h. Subsequently, the MTT and medium was removed and 100 μl DMSO was added to dissolve the formazan crystals formed by the viable cells. Absorbance was determined at 570 nm by Opsys microplate reader (Dynex Technologies, Chantilly, VA). The IC 50 (concentration required to inhibit the growth by 50%) values were calculated from the survival curves using modified Bliss method [23] . Resistance fold (Rf) was calculated by dividing the IC 50 for the resistant cells with or without an inhibitor by that of the parental cells without an inhibitor. The concentrations of voruciclib as a potential reversal agent used in this study were 1 µM and 5 µM. Verapamil (5 µM) and FTC (5 µM) were used as a positive control inhibitor of ABCB1 and ABCG2, respectively.
Doxorubicin and mitoxantrone intracellular accumulation assay
Cells grown on sterile coverslips were treated with or without 5 μM voruciclib for 1 h. Subsequently, the SW620 and SW620/AD300 cells were incubated with 5 μM doxorubicin and the NCI-H460 and NCI-H460/ MX20 cells were incubated with 5 μM mitoxantrone for 2 h, followed by examination under the fluorescence microscope. ]-mitoxantrone as previously described [24] .
Preparation of total cell lysates
The voruciclib treated and un-treated cells were harvested and lysed with lysis buffer for 30 min on ice, followed by centrifugation at 12, 000 rpm at 4°C for 20 min. The supernatant was collected and protein concentration was determined by bicinchoninic acid (BCA™)-based protein assay (Thermo Scientific, Rockford, IL).
Western blotting
Equal amounts of total cell lysates (60 μg protein) were resolved by SDS-PAGE and transferred onto polyvinylidene fluoride membranes. The membranes were blocked with 5% skim milk dissolved in TBST buffer (10 mmol·L− 1 Tris-HCL, 150 mmol·L− 1 NaCl and 0.1% Tween20 pH 8.0) to block nonspecific binding. The blot was probed with primary antibody C219 (ABCB1 specific; dilution 1:500), BXP-21 (ABCG2 specific; dilution 1:500), and 13E5 (β-actin specific; dilution 1:1000), overnight at 4°C, followed by incubation with HRP (horseradish peroxidase)-conjugated secondary antibody, on the next day. The enhanced chemiluminescence detection system was used to detect the protein-antibody complex. The expression of β-actin was used as a loading control and the protein expression was quantified by ImageJ 1.47v Software (NIH, MD)
Immunofluorescence
The cells were treated with 5 μM voruciclib for 24, 48, 72, and 96 h and the fluorescent detection for ABCB1 and ABCG2 was performed as previously described [25, 26] .
ATPase assay
The vanadate-sensitive ATPase activity of ABCB1 and ABCG2 in crude membranes of High-five insect cells was measured in the presence of voruciclib (0 to 40 μM) by PREDEASY ATPase Kits with modified protocols, as previously described [22, 27] .
Apoptosis analysis
Voruciclib (5 μM) alone or in combination with either paclitaxel or mitoxantrone was tested for its ability to induce apoptosis in parental and ABCB1-or ABCG2-overexpressing cells. Flow cytometric analysis was performed as previously described using FL-1 and FL-2 filters of a BD Accuri™ C6 flow cytometer [28, 29] .
Induced-fit docking of Voruciclib into human homology ABCB1 and ABCG2
Human homology ABCB1 model based on refined mouse ABCB1 (PDB ID: 4M1M) was provided by S. Aller and the docking grid was refined within the transmembrane region as previously described [19, 30] . Our previous grid on human homology ABCG2 on centroid of Arg482 was used for docking on ABCG2 [31] . The structure of voruciclib was built in Maestro and prepared by Ligprep 3.3. The energy minimized structure of voruciclib was then subjected to Glide v6.6 XP (extra precision) docking. In order to generate a closer conformation of ABCB1 or ABCG2 to the shape of voruciclib and to lead to better binding affinity complex, the IFD (induced-fit docking) protocol was carried out using Glide v6.6 (Schrödinger, USA, 2015) in this study. Generally, at the transmembrane domain of protein, the best scored voruciclib from XP run was used to generate the grid for IFD docking calculation. The default Glide IFD protocol was followed and the docking score (kcal/mol) was calculated. Top scoring docked complexes of ABCB1-voruciclib and ABCG2- voruciclib were used to interaction analysis and graphic representation. All computations were carried out on a 6-core Intel Xeon Processor with a Mac OS.
Statistical analysis
All experiments were repeated at least three times and the differences were determined using the two-tailed student's t-test (Microsoft Excel 2010) and statistical significance was determined at p < 0.05.
Results

Cytotoxic effects of voruciclib on parental and ABCB1-or ABCG2-overexpressing cells
Prior to investigating the reversal effects of voruciclib, its cytotoxicity was evaluated using the MTT assay. As shown in Fig. 1 , more than 85% of both parental and ABCB1-or ABCG2-overexpressing cells survived at the concentration of 5 μM voruciclib, indicating that voruciclib is safe to be used up to a concentration of 5 μM. Thus, voruciclib at 1 and 5 μM was tested in combination with chemotherapeutic drugs for its ability to reverse ABCB1 and ABCG2-mediated MDR.
Effect of voruciclib on ABCB1 substrates in cell lines overexpressing ABCB1
The effect of voruciclib on ABCB1 substrates was determined by conducting cell survival assays. Paclitaxel and doxorubicin exhibited much higher IC 50 to ABCB1-overexpressing SW620/AD300 cells than the parental SW620 cells. Voruciclib at 1 and 5 μM significantly sensitized SW620/AD300 cells to the substrates of ABCB1, as shown in Table 1 . Similar reduction in IC 50 values of paclitaxel and doxorubicin was observed in transfected LLC-PK1/ MDR1 cells on exposure to 1 or 5 μM voruciclib. Verapamil at 5 μM was used a positive control inhibitor while cisplatin, a non-ABCB1 substrate, was used a negative control.
Effect of voruciclib on ABCG2 substrates in cell lines overexpressing wild-type and mutant ABCG2
Since polymorphism in ABCG2 is known to alter substrate and antagonist specificity [14] , the effects of voruciclib were determined in both wild-type (R482) and mutant (R482G and R482T) ABCG2. As shown in Table 2 , voruciclib at 1 and 5 μM, produced a concentration-dependent decrease in ABCG2-mediated resistance to mitoxantrone and SN38 as indicated by the decrease in the IC 50 values in HEK/ ABCG2-R482, HEK/ ABCG2-R482G and HEK/ABCG2-R482T cells. In addition, voruciclib showed similar effect in AB-CG2-overexpressing N C I -H 4 6 0 / M X 2 0 cells (Table  3) . Meanwhile, treatment with voruciclib did not significantly change the IC 50 value of mitoxantrone and SN-38 in parental 
Effect of voruciclib on cells overexpressing ABCC1 and ABCC10
To further investigate the specificity of voruciclib, its reversal activity was tested in cells overexpressing ABCC1 and ABCC10. As shown in Table 4 , voruciclib at 1 and 5 μM did not significantly decrease the IC 50 value of vincristine (ABCC1 substrate) in ABCC1-overexpressing HEK293/ABCC1 cells. However, voruciclib treatment showed a partial decrease in IC 50 value of paclitaxel (ABCC10 substrate) on ABCC10-overexpressing HEK293/ABCC10 cells, suggesting that voruciclib partially sensitizes ABCC10-overexpressing cells to its substrate drugs but has no effect on ABCC1-mediated MDR.
Effect of voruciclib on the intracellular accumulation of doxorubicin or mitoxantrone in ABCB1-or ABCG2-overexpressing cells
Intracellular accumulation of doxorubicin or mitoxantrone was assessed to understand the mechanism by which voruciclib attenuates ABCB1 or ABCG2-mediated MDR. Based on their fluorescence intensity, doxorubicin or mitoxantrone were found to be accumulated in the cytoplasm and nuclei of SW620 or NCI-H460 cells ( Fig. 2A and 2B) . Contrastingly, much weaker fluorescence was observed in the resistant SW620/AD300 or NCI-H460/MX20 cells. Pretreatment with voruciclib at 5 μM significantly increased the fluorescence intensity in resistant cells with little or no change in the parental cells. Similar results were obtained for 5 μM of verapamil or FTC. . Equal amounts of total cell lysates were used for each sample. Western blot analysis was performed and grayscale ratios of ABCB1/β-actin and ABCG2/ β-actin were determined with Image J. The grayscale ratios were proportional to the ABCB1 or ABCG2 protein levels (B, D). The differences were not statistically significant (p > 0.05).The effect of voruciclib at 5 μM on the subcellular localization of ABCB1 or ABCG2 in ABCB1-overexpressing SW620/AD300 (E) or ABCG2-overexpressing NCI-H460/MX20 cells (F) Scale bar, 10 μ m. PI (propidium iodide, red) and DAPI (blue) counterstains the nuclei.
Effect of voruciclib on the cellular accumulation of [ 3 H]-paclitaxel or [ 3 H]-mitoxantrone in ABCB1-or ABCG2-overexpressing cells In order to quantify the accumulation effects of voruciclib, the cellular accumulation of [
Effect of voruciclib on the expression and intracellular localization of ABCB1 or ABCG2
Western blot analysis was carried out to determine the effect of voruciclib on the expression of ABCB1 or ABCG2. There was no significant change in the protein expression Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry of ABCB1 or ABCG2 in SW620/AD300 ( Fig. 4A and 4B ) or NCI-H460/MX20 ( Fig. 4C and 4D ) cells, respectively upon voruciclib (5 µM) treatment for 96 h. Although, Western blotting results confirmed that voruciclib does not alter the expression of ABCB1 or ABCG2, its effects on the translocation of ABCB1 or ABCG2 from plasma membrane to cytoplasm were uncertain. Immunofluorescence staining of the SW620/AD300 (Fig. 4E) and NCI-H460/MX20 (Fig. 4F ) cells showed that voruciclib (5µM) did not significantly change the sub cellular distribution of ABCB1 or ABCG2.
Effect of voruciclib on the ATPase activity of ABCB1 or ABCG2
To assess the effect of voruciclib on the ATPase activity ofABCB1 or ABCG2, we measured ABCB1 or ABCG2-mediated ATP hydrolysis in the presence of voruciclib. Voruciclib stimulated the vanadate-sensitive ATPase activity of ABCB1 ( Fig. 5A and 5B) or ABCG2 ( Fig.  5C and 5D ) in a concentration-dependent manner with a fold-stimulation of 3.2 or 2.2 -fold, respectively of the basal activity. The concentration of voruciclib required to obtain 50% of maximal stimulation is 0.72 μM or 0.77 μM for ABCB1 or ABCG2, respectively.
Effect of voruciclib on apoptosis of ABCB1-or ABCG2-overexpressing cells
Apoptosis assay was carried out to determine the percentage of apoptotic cells induced by indicated regimens. As shown in Fig. 6A and 6B, in the absence of paclitaxel, the apoptotic cell percentage in parental SW620 and ABCB1-overexpressing SW620/AD300 cells was not significantly affected by voruciclib (5 μM) or verapamil (5 μM). On treatment with paclitaxel (50 nM), the percentage of apoptotic cells increased significantly from 1.9% to 28.5% in SW620 cells (Fig. 6A and 6C ). However, paclitaxel (50 nM) did not significantly increase the percentage of apoptotic cells in SW620/AD300 cells ( Fig. 6B and 6D ). Interestingly, voruciclib or verapamil, at 5 μM, significantly increased the level of apoptosis induced by paclitaxel in SW620/AD300 cells from approximately 20% to 42.7% and 44%, respectively.
Furthermore, in the absence of mitoxantrone, the percentage of apoptotic cells was similar and remains unaffected by voruciclib (5 μM) or FTC (5 μM) in parental NCI-H460 and NCI-H460/MX20 cells ( Fig. 6E and 6F ). Mitoxantrone (50 nM) increased the percentage of apoptotic cells from 6% to 19.3% in H460 cells (Fig. 6G ) while no significant change was observed in NCI-H460/MX20 cells (Fig. 6H) . Moreover, voruciclib or FTC, at 5 μM, significantly increased the level of apoptosis induced by mitoxantrone in NCI-H460/MX20 cells from approximately 24.8% to 53.9% and 54.0%, respectively. 
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Interaction analysis of vorucicilib-ABCB1 and v o r u c i cl i b -A B -CG2 induced-fit docked complexes
The best scored pose of voruciclib exhibited a high docking score of -11.419 kcal/ mol within the transmembrane domain of human homology ABCB1. As shown in Fig. 7A , the 2-chlor-4-trifluormethyl phenyl ring was stabilized by nearby residues Met69, Phe336, Ile340, Ala729, Phe732 and Phe983 through hydrophobic interactions. Moreover, the side chain phenyl ring of residue Phe983 formed a π-π stacking interaction with the phenyl ring of voruciclib. An intra-ligand hydrogen bond was formed in between 5-hydroxyl and ketone group of 5, 7-dihydroxyl chromone ring of voruciclib (OH·· OC, 1.9 Å). The 5-hydroxyl group formed an electrostatic interaction with side chain amino group of Gln 990 (HO·· H 2 N-Gln990, 2.2 Å). The 7-hydroxyl group formed another electrostatic interaction with side chain hydroxyl group of Tyr307 (OH·· OH-Tyr307, 2.5 Å). The 2-hydroxylmethyl group on the pyr- Similarly, voruciclib exhibited a docking score of -10.304 kcal/ mol within the transmembrane domain of human homology of ABCG2 (Fig.7B) . Two π-π stacking interactions were observed between the 2-chlor-4-trifluormethyl phenyl ring and the aromatic side chains of His 630 and Trp 627. Besides, multiple hydrogen interactions were formed between voruciclib and nearby residues. The 5-hydroxyl group of 5, 7-dihydroxyl chromone ring formed two hydrogen bonds with guanidine group of Arg 465 (O·· H 2 N-Arg 465, 2.7 Å and 2.1 Å). The positively charged pyrrolidine ring formed a hydrogen bond with side chain of Asn629 (NH·· OC-Asn629, 2.0 Å). The 2-hydroxylmethyl group on the pyrrolidine ring of voruciclib formed another hydrogen bond with side chain of Asn584 (OH·· OC-Asn584, 2.0 Å). The ketone group of 5, 7-dihydroxyl chromone ring of voruciclib formed a hydrogen bond with side chain of Trp 627 (CO·· HN-Trp627, 2.3 Å).
Discussion
The CDK targeting agents such as voruciclib, ribociclib, palbociclib, daniciclib, and abemaciclib have shown potent anti-cancer activity in metastatic breast cancer, myeloma, and neuroblastoma [32, 33] . However, except abemaciclib none of these agents have been tested for their ability to overcome MDR in cancer cells [34] .
One major finding of this study was that voruciclib (1 and 5 μM) significantly enhanced the sensitivity of ABCB1-or ABCG2-overexpressing cells to their respective substrate chemotherapeutic drugs. As evident from our MTT results, voruciclib produced a significant decrease in the IC 50 values of paclitaxel and doxorubicin in ABCB1-overexpressing cells or mitoxantrone and SN-38 in ABCG2-overexpressing cells. Studies in the past have shown that mutation at position 482 in ABCG2 affects inhibitory activity such as that of novobiocin [14, 35, 36] . Convincingly, our results showed that voruciclib inhibits the activity of both wild-type (R482) and mutant (R482G and R482T) ABCG2. Furthermore, voruciclib (5 μM) partially reversed ABCC10 but not ABCC1-mediated MDR. 
